The Impact of COVID-19 Regulations on Adherence to Recombinant Human Growth Hormone Therapy: Evidence from Real-World Data

Worldwide regulations during COVID-19 positively and negatively impacted self-management in paediatric patients with chronic medical conditions. We investigated the impact of on adherence to recombinant human growth hormone (r-hGH) therapy disorders, using real-world data extracted March 2019–February 2020 (before COVID-19) 2020–February 2021 (during from easypod™ connect ecosystem. Data three measures were analysed: stringency index (SI), school closure stay-at-home. The mean SI, proportion days required or stay-at-home categorised as high versus medium/low based 75th percentile. Adherence was optimal (≥85%) suboptimal (<85%). available for 8915 before 7606 COVID-19. A SI (mean ≥68) a (≥88%) resulted an increase pre-COVID-19 (p < 0.001). Stay-at-home requirements showed no statistically significant effect = 0.13). Stringent improved r-hGH supported by connected digital health technologies. Insights into patient behavior this time are useful understand potential influences strategies improve long-term r-hGH.